Kennedy SH. Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues Clin Neurosci. 2008;10:271–7.
Huey NS, Guan NC, Gill JS, Hui KO, Sulaiman AH, Kunagasundram S. Core symptoms of major depressive disorder among palliative care patients. Int J Environ Res Public Health. 2018;15:1758.
Fava M, Kendler KS. Major depressive disorder. Neuron. 2000;28:335–41.
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386–9.
Zhang X, Wang L, Huang F, Li J, Xiong L, Xue H, et al. Gene-environment interaction in postpartum depression: a Chinese clinical study. J Affect Disord. 2014;165:208–12.
Chiriţă AL, Gheorman V, Bondari D, Rogoveanu I. Current understanding of the neurobiology of major depressive disorder. Rom J Morphol Embryol. 2015;56:651–8.
Lotrich FE. Gene-environment interactions in geriatric depression. Psychiatr Clin North Am. 2011;34:357–76.
Fakhoury M. Revisiting the serotonin hypothesis: implications for major depressive disorders. Mol Neurobiol. 2016;53:2778–86.
Pacher P, Kohegyi E, Kecskemeti V, Furst S. Current trends in the development of new antidepressants. Curr Med Chem. 2001;8:89–100.
Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci. 2006;7:137–51.
Leistner C, Menke A. Hypothalamic-pituitary-adrenal axis and stress. Handb Clin Neurol. 2020;175:55–64.
Mello AF, Mello MF, Carpenter LL, Price LH. Update on stress and depression: the role of the hypothalamic-pituitary-adrenal (HPA) axis. Braz J Psychiatry. 2003;25:231–8.
Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron. 2002;34:13–25.
Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455:894–902.
Aguilera G, Liu Y. The molecular physiology of CRH neurons. Front Neuroendocrinol. 2012;33:67–84.
Jurek B, Slattery DA, Hiraoka Y, Liu Y, Nishimori K, Aguilera G, et al. Oxytocin regulates stress-induced Crf gene transcription through CREB-regulated transcription coactivator 3. J Neurosci. 2015;35:12248–60.
Liu Y, Coello AG, Grinevich V, Aguilera G. Involvement of transducer of regulated cAMP response element-binding protein activity on corticotropin releasing hormone transcription. Endocrinology. 2010;151:1109–18.
Liu Y, Knobloch HS, Grinevich V, Aguilera G. Stress induces parallel changes in corticotrophin-releasing hormone (CRH) Transcription and nuclear translocation of transducer of regulated cAMP response element-binding activity 2 in hypothalamic CRH neurones. J Neuroendocrinol. 2011;23:216–23.
Martín F, Núñez C, Marín MT, Laorden ML, Kovács KJ, Milanés MV. Involvement of noradrenergic transmission in the PVN on CREB activation, TORC1 levels, and pituitary-adrenal axis activity during morphine withdrawal. PLoS One. 2012;7:e31119.
Johannessen M, Delghandi MP, Moens U. What turns CREB on? Cell Signal. 2004;16:1211–27.
Andrisani OM. CREB-mediated transcriptional control. Crit Rev Eukaryot Gene Expr. 1999;9:19–32.
Wei J, Dong S, Bowser RK, Khoo A, Zhang L, Jacko AM, et al. Regulation of the ubiquitylation and deubiquitylation of CREB-binding protein modulates histone acetylation and lung inflammation. Sci Signal. 2017;10:eaak9660.
Vendel AC, McBryant SJ, Lumb KJ. KIX-mediated assembly of the CBP-CREB-HTLV-1 tax coactivator-activator complex. Biochemistry. 2003;42:12481–7.
Dal Peraro M, Alber F, Carloni P. Ser133 phosphate-KIX interactions in the CREB-CBP complex: an ab initio molecular dynamics study. Eur Biophys J. 2001;30:75–81.
Xiong Y, Zhang M, Li Y. Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors. Curr Med Chem. 2020;27:5583–98.
Zhou F, Liu Q, Zhang L, Zhu Q, Wang S, Zhu K, et al. Selective inhibition of CBP/p300 HAT by A-485 results in suppression of lipogenesis and hepatic gluconeogenesis. Cell Death Dis. 2020;11:745.
He ZX, Wei BF, Zhang X, Gong YP, Ma LY, Zhao W. Current development of CBP/p300 inhibitors in the last decade. Eur J Med Chem. 2021;209:112861.
Cope JL, Regev L, Chen Y, Korosi A, Rice CJ, Ji S, et al. Differential contribution of CBP:CREB binding to corticotropin-releasing hormone expression in the infant and adult hypothalamus. Stress. 2014;17:39–50.
Wölfl S, Martinez C, Majzoub JA. Inducible binding of cyclic adenosine 3’,5’-monophosphate (cAMP)-responsive element binding protein (CREB) to a cAMP-responsive promoter in vivo. Mol Endocrinol. 1999;13:659–69.
Sterrenburg L, Gaszner B, Boerrigter J, Santbergen L, Bramini M, Roubos EW, et al. Sex-dependent and differential responses to acute restraint stress of corticotropin-releasing factor-producing neurons in the rat paraventricular nucleus, central amygdala, and bed nucleus of the stria terminalis. J Neurosci Res. 2012;90:179–92.
Louwies T, Orock A, Greenwood-Van Meerveld B. Stress-induced visceral pain in female rats is associated with epigenetic remodeling in the central nucleus of the amygdala. Neurobiol Stress. 2021;15:100386.
Louwies T, Greenwood-Van Meerveld B. Sex differences in the epigenetic regulation of chronic visceral pain following unpredictable early life stress. Neurogastroenterol Motil. 2020;32:e13751.
Solomon ER, Caldwell KK, Allan AM. Developmental arsenic exposure is associated with sex differences in the epigenetic regulation of stress genes in the adult mouse frontal cortex. Toxicol Appl Pharmacol. 2020;391:114920.
Wang B, Wang P, Parobchak N, Treff N, Tao X, Wang J, et al. Integrated RNA-seq and ChIP-seq analysis reveals a feed-forward loop regulating H3K9ac and key labor drivers in human placenta. Placenta. 2019;76:40–50.
Neutzner M, Neutzner A. Enzymes of ubiquitination and deubiquitination. Essays Biochem. 2012;52:37–50.
Dong S, Zhao J, Wei J, Bowser RK, Khoo A, Liu Z, et al. F-box protein complex FBXL19 regulates TGFβ1-induced E-cadherin down-regulation by mediating Rac3 ubiquitination and degradation. Mol Cancer. 2014;13:76.
Zhao J, Wei J, Mialki RK, Mallampalli DF, Chen BB, Coon T, et al. F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation. Nat Immunol. 2012;13:651–8.
Wang F, Ning S, Yu B, Wang Y. USP14: structure, function, and target inhibition. Front Pharmacol. 2021;12:801328.
Hu M, Li P, Song L, Jeffrey PD, Chenova TA, Wilkinson KD, et al. Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. Embo j. 2005;24:3747–56.
Wang D, Ma H, Zhao Y, Zhao J. Ubiquitin-specific protease 14 is a new therapeutic target for the treatment of diseases. J Cell Physiol. 2021;236:3396–405.
Banerjee C, Roy M, Mondal R, Chakraborty J. USP14 as a therapeutic target against neurodegeneration: a rat brain perspective. Front Cell Dev Biol. 2020;8:727.
Lipinski M, Del Blanco B, Barco A. CBP/p300 in brain development and plasticity: disentangling the KAT’s cradle. Curr Opin Neurobiol. 2019;59:1–8.
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010;160:1577–9.
McGrath JC, Lilley E. Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol. 2015;172:3189–93.
Wang Y, Liu L, Gu JH, Wang CN, Guan W, Liu Y, et al. Salt-inducible kinase 1-CREB-regulated transcription coactivator 1 signalling in the paraventricular nucleus of the hypothalamus plays a role in depression by regulating the hypothalamic-pituitary-adrenal axis. Mol Psychiatry. 2024;29:1660–70.
Jiang B, Wang H, Wang JL, Wang YJ, Zhu Q, Wang CN, et al. Hippocampal salt-inducible Kinase 2 plays a role in depression via the CREB-Regulated transcription Coactivator 1-cAMP response element binding-brain-derived neurotrophic factor pathway. Biol Psychiatry. 2019;85:650–66.
Guan W, Xu DW, Ji CH, Wang CN, Liu Y, Tang WQ, et al. Hippocampal miR-206-3p participates in the pathogenesis of depression via regulating the expression of BDNF. Pharmacol Res. 2021;174:105932.
Song L, Wang H, Wang YJ, Wang JL, Zhu Q, Wu F, et al. Hippocampal PPARα is a novel therapeutic target for depression and mediates the antidepressant actions of fluoxetine in mice. Br J Pharmacol. 2018;175:2968–87.
Tang WQ, Liu Y, Ji CH, Gu JH, Chen YM, Huang J, et al. Virus-mediated decrease of LKB1 activity in the mPFC diminishes stress-induced depressive-like behaviors in mice. Biochem Pharmacol. 2022;197:114885.
Chen YM, Fan H, Huang J, Shi TS, Li WY, Wang CN, et al. Hippocampal F3/Contactin plays a role in chronic stress-induced depressive-like effects and the antidepressant actions of vortioxetine in mice. Biochem Pharmacol. 2022;202:115097.
Ji CH, Gu JH, Liu Y, Tang WQ, Guan W, Huang J, et al. Hippocampal MSK1 regulates the behavioral and biological responses of mice to chronic social defeat stress: involving of the BDNF-CREB signaling and neurogenesis. Biochem Pharmacol. 2022;195:114836.
Wang Y, Gu JH, Liu L, Liu Y, Tang WQ, Ji CH, et al. Hippocampal PPARα Plays a role in the pharmacological mechanism of vortioxetine, a multimodal-acting antidepressant. Front Pharmacol. 2021;12:673221.
Jiang B, Wang YJ, Wang H, Song L, Huang C, Zhu Q, et al. Antidepressant-like effects of fenofibrate in mice via the hippocampal brain-derived neurotrophic factor signalling pathway. Br J Pharmacol. 2017;174:177–94.
Liu Y, Tang W, Ji C, Gu J, Chen Y, Huang J, et al. The selective SIK2 inhibitor ARN-3236 produces strong antidepressant-like efficacy in mice via the hippocampal CRTC1-CREB-BDNF pathway. Front Pharmacol. 2020;11:624429.
Wang H, Zhao Y, Wang YJ, Song L, Wang JL, Huang C, et al. Antidepressant-like effects of tetrahydroxystilbene glucoside in mice: Involvement of BDNF signaling cascade in the hippocampus. CNS Neurosci Ther. 2017;23:627–36.
Romero FA, Murray J, Lai KW, Tsui V, Albrecht BK, An L, et al. GNE-781, a highly advanced potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein, binding protein (CBP). J Med Chem. 2017;60:9162–83.
Min JW, Lü L, Freeling JL, Martin DS, Wang H. USP14 inhibitor attenuates cerebral ischemia/reperfusion-induced neuronal injury in mice. J Neurochem. 2017;140:826–33.
Seasholtz AF, Thompson RC, Douglass JO. Identification of a cyclic adenosine monophosphate-responsive element in the rat corticotropin-releasing hormone gene. Mol Endocrinol. 1988;2:1311–9.
Spengler D, Rupprecht R, Van LP, Holsboer F. Identification and characterization of a 3’,5’-cyclic adenosine monophosphate-responsive element in the human corticotropin-releasing hormone gene promoter. Mol Endocrinol. 1992;6:1931–41.
Liu Y, Kamitakahara A, Kim AJ, Aguilera G. Cyclic adenosine 3’,5’-monophosphate responsive element binding protein phosphorylation is required but not sufficient for activation of corticotropin-releasing hormone transcription. Endocrinology. 2008;149:3512–20.
Di Stefano V, Wang B, Parobchak N, Roche N, Rosen T. RelB/p52-mediated NF-κB signaling alters histone acetylation to increase the abundance of corticotropin-releasing hormone in human placenta. Sci Signal. 2015;8:ra85.
Weinert BT, Narita T, Satpathy S, Srinivasan B, Hansen BK, Schölz C, et al. Time-resolved analysis reveals rapid dynamics and broad scope of the CBP/p300 acetylome. Cell. 2018;174:231–44.
Henry RA, Kuo YM, Andrews AJ. Differences in specificity and selectivity between CBP and p300 acetylation of histone H3 and H3/H4. Biochemistry. 2013;52:5746–59.
Kawasaki H, Eckner R, Yao TP, Taira K, Chiu R, Livingston DM, et al. Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature. 1998;393:284–9.
Chakraborty R, Ostriker AC, Xie Y, Dave JM, Gamez-Mendez A, Chatterjee P, et al. Histone acetyltransferases p300 and CBP coordinate distinct chromatin remodeling programs in vascular smooth muscle plasticity. Circulation. 2022;145:1720–37.
Grishina I, Debus K, García-Limones C, Schneider C, Shresta A, García C, et al. SIAH-mediated ubiquitination and degradation of acetyl-transferases regulate the p53 response and protein acetylation. Biochim Biophys Acta. 2012;1823:2287–96.
Dong S, Wei J, Bowser RK, Chen BB, Mallampalli RK, Miao J, et al. SCF FBXW17 E3 ubiquitin ligase regulates FBXL19 stability and cell migration. J Cell Biochem. 2021;122:326–34.
Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci. 2001;114:2363–73.
Valor LM, Viosca J, Lopez-Atalaya JP, Barco A. Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders. Curr Pharm Des. 2013;19:5051–64.
Zanger K, Radovick S, Wondisford FE. CREB binding protein recruitment to the transcription complex requires growth factor-dependent phosphorylation of its GF box. Mol Cell. 2001;7:551–8.
Impey S, Fong AL, Wang Y, Cardinaux JR, Fass DM, Obrietan K, et al. Phosphorylation of CBP mediates transcriptional activation by neural activity and CaM kinase IV. Neuron. 2002;34:235–44.
Xu W, Chen H, Du K, Asahara H, Tini M, Emerson BM, et al. A transcriptional switch mediated by cofactor methylation. Science. 2001;294:2507–11.
Rouaux C, Loeffler JP, Boutillier AL. Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. Biochem Pharmacol. 2004;68:1157–64.
Swanson LW, Kuypers HG. The paraventricular nucleus of the hypothalamus: cytoarchitectonic subdivisions and organization of projections to the pituitary, dorsal vagal complex, and spinal cord as demonstrated by retrograde fluorescence double-labeling methods. J Comp Neurol. 1980;194:555–70.
Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol. 2004;44:525–57.
Herman JP, McKlveen JM, Ghosal S, Kopp B, Wulsin A, Makinson R, et al. Regulation of the Hypothalamic-Pituitary-Adrenocortical Stress Response. Compr Physiol. 2016;6:603–21.
Wei J, Mialki RK, Dong S, Khoo A, Mallampalli RK, Zhao Y, et al. A new mechanism of RhoA ubiquitination and degradation: roles of SCF(FBXL19) E3 ligase and Erk2. Biochim Biophys Acta. 2013;1833:2757–64.
Zhao J, Mialki RK, Wei J, Coon TA, Zou C, Chen BB, et al. SCF E3 ligase F-box protein complex SCF(FBXL19) regulates cell migration by mediating Rac1 ubiquitination and degradation. Faseb j. 2013;27:2611–9.
Lappe-Siefke C, Loebrich S, Hevers W, Waidmann OB, Schweizer M, Fehr S, et al. The ataxia (axJ) mutation causes abnormal GABAA receptor turnover in mice. PLoS Genet. 2009;5:e1000631.
Waddell AR, Huang H, Liao D. CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers. Cancers (Basel). 2021;13:2872.
Giles RH, Peters DJ, Breuning MH. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 1998;14:178–83.
Dancy BM, Cole PA. Protein lysine acetylation by p300/CBP. Chem Rev. 2015;115:2419–52.
Hegarty SV, O’Leary E, Solger F, Stanicka J, Sullivan AM, O’Keeffe GW. A small molecule activator of p300/CBP histone acetyltransferase promotes survival and neurite growth in a cellular model of Parkinson’s disease. Neurotox Res. 2016;30:510–20.
Ortuno D, Carlisle HJ, Miller S. Does inactivation of USP14 enhance degradation of proteasomal substrates that are associated with neurodegenerative diseases? F1000Res. 2016;5:137.